source
- Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin LymphomaAlex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.onclive · 2mo ago↗ source
- STAT+: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with reviewSanofi has asked the FDA to pull its type 1 diabetes drug out of Commissioner Marty Makary’s new speedy drug review program.STAT · 2mo ago↗ source
- Dr Sznol on Biomarkers of Response in Metastatic MelanomaMario Sznol, MD, discusses the uncertainties around predicting benefit with immune checkpoint inhibitors in metastatic melanoma.